Hesperidin
CAS 520-26-3
Hesperidin (CAS 520-26-3) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 10 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 64213.4 nM | 15 | - |
| - | Potency | 46052.854545454546 nM | 11 | - |
| - | MIC | 200 ug.mL-1 | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| HESPERIDIN | 5281 | SU | MTHSPL |
| hesperidin | 5281 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Hesperidin used for in pharmaceutical contexts?
Hesperidin (CAS 520-26-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Hesperidin?
Hesperidin has 10 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Asthenia, Decreased appetite, Hypoaesthesia, Muscle spasms, Neuropathy peripheral. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Hesperidin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Hesperidin with EU status "permitted".
What clinical phase is Hesperidin in?
Hesperidin is rendered with ChEMBL max phase 3.